Research Topics
Species | N LyckeSummaryCountry: Sweden Publications
| Collaborators
|
Detail Information
Publications
From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and toleranceNils Lycke
Department of Clinical Immunology, University of Goteborg, Guldhedsgatan 10A, S41346 Göteborg, Sweden
Immunol Lett 97:193-8. 2005..Therefore, targeting to APC in the absence or presence of the CTA1-enzyme appears to be an effective means to control tolerance and active protective IgA immunity...- Recent progress in mucosal vaccine development: potential and limitationsNils Lycke
Center for Mucosal Immunobiology and Vaccines MIVAC, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Sweden
Nat Rev Immunol 12:592-605. 2012..Here, I discuss the expanding knowledge and strategies used in the development of mucosal vaccines... - ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunityNils Lycke
Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
Ann N Y Acad Sci 1029:193-208. 2004..For example, the expression of CD86 in vivo was a prominent feature of the enzymatically active CT or CTA1-DD adjuvants. By contrast, CD80 expression appeared not to be important in CTA1-augmented APCs for an adjuvant function... - Targeted vaccine adjuvants based on modified cholera toxinNils Lycke
Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
Curr Mol Med 5:591-7. 2005.... - The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunityN Lycke
Department of Clinical Immunology, University of Goteborg, S 413 46, Goteborg, Sweden
Vaccine 19:2542-8. 2001..These results support the notion that the CTA1-DD adjuvant can repeatedly be used in the clinic without loss of efficacy even when pre-existing anti-CTA1 antibody levels are high... - The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responsesN Lycke
Department of Clinical Immunology, University of Goteborg, S 413 46 Goteborg, Sweden
Curr Opin Mol Ther 3:37-44. 2001..The enhancing effect is associated with enlarged germinal centers, and binding of CTA1-DD to the B-cells strongly upregulates co-stimulatory molecules and counteracts apoptosis by inducing intracellular Bcl-2... - Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protectionN Lycke
Department of Medical Microbiology and Immunology, University of Goteborg, Sweden
J Immunol 163:913-9. 1999..This study unequivocally demonstrates a direct relationship between mucosal transport of secretory SIgA and intestinal immune protection... - Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxinsN Lycke
MIVAC, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
Mucosal Immunol 3:556-66. 2010.... - From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOMNils Lycke
Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
Cell Microbiol 6:23-32. 2004..Thus, we have demonstrated that rationally designed vectors consisting of CTA1-DD and ISCOMS may provide a novel strategy for the generation of potent and safe mucosal vaccines... - The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunizationA A Akhiani
Department of Clinical Immunology, , , Sweden
Scand J Immunol 63:97-105. 2006..These findings clearly demonstrate that CTA1-DD adjuvant is a promising candidate to be further exploited in the development of a mucosal vaccine against H. pylori infection... - The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating abilityA Eriksson
Department of Clinical Immunology, , S-413 46, , Sweden
Vaccine 22:185-93. 2003..Collectively our data suggest that CTA1-DD acted via enhanced co-stimulation, which holds promise as to the use of CTA1-DD as a non-toxic adjuvant in future vaccines for human use... - Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formationYu Fang
Department of Microbiology and Immunology, Mucosal Immunobiology and Vaccine Research Center, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
J Immunol 185:2935-41. 2010.... - Strong differential regulation of serum and mucosal IgA responses as revealed in CD28-deficient mice using cholera toxin adjuvantEva Gärdby
Department of Clinical Immunology, University of Goteborg, Goteborg, Sweden
J Immunol 170:55-63. 2003..Although CT is known to strongly up-regulate B7-molecules, we have demonstrated that it acts as a potent mucosal adjuvant in the absence of CD28, suggesting that alternative costimulatory pathways are involved... - Impaired mucosal immune responses in interleukin 4-targeted miceM Vajdy
Department of Medical Microbiology and Immunology, University of Goteborg, Sweden
J Exp Med 181:41-53. 1995..Our findings demonstrate that IL-4 and probably functional Th2 cells are required for induction of gut mucosal antibody responses... - CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccineDubravka Grdic Eliasson
Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Goteborg, Box 435, 40530 Goteborg, Sweden
Vaccine 26:1243-52. 2008..This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine... - Immunological memory in B-cell-deficient mice conveys long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid recruitment of T cellsM Johansson
Department of Medical Microbiology and Immunology, , , Sweden
Immunology 102:199-208. 2001..Thus, long-term protection in the genital tract against C. trachomatis infection is conveyed by IFN-gamma-producing CD4+ memory T cells, which appear to be maintained in the absence of antibodies and local antigen deposition... - Surface and gene expression of immunoglobulin E receptors on mast cells and mast-cell numbers in interleukin-4-gene knockout miceX J Chen
Department of Pathology, Institute of Laboratory Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
Immunology 96:544-50. 1999..This was unexpected in view of previous findings suggesting that IL-4, in concert with stem cell factor and IL-3, stimulates the proliferation and differentiation of mast cells in vitro... - Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infectionEllen Marks
Department of Microbiology and Immunology, Mucosal Immunobiology and Vaccine Research Center, Institute of Biomedicine, Gothenburg University, Box 435, 40530 Gothenburg, Sweden
Infect Immun 75:4638-47. 2007..Both the CD28-deficient and the ICOS-deficient mice demonstrated poor specific antibody production, supporting the fact that antibodies are not needed for protection against genital tract chlamydial infections... - Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxinDubravka Grdic
Department of Clinical Immunology, , , Sweden
J Immunol 175:5192-202. 2005..These events may explain why CT-conjugated Ag is substantially more immunogenic than Ag admixed with soluble CT and why CTB-conjugated Ag can tolerize immune responses when given orally or at other mucosal sites... - Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cellsAli A Akhiani
Department of Clinical Immunology, University of Goteborg, Goteborg, Sweden
J Immunol 169:6977-84. 2002..We conclude that IL-12 and Th1 responses are crucial for H. pylori-specific protective immunity... - A unique population of extrathymically derived alpha beta TCR+CD4-CD8- T cells with regulatory functions dominates the mouse female genital tractMartina Johansson
Department of Clinical Immunology, University of Goteborg, S 413 46 Goteborg, Sweden
J Immunol 170:1659-66. 2003..A large fraction of the cells expressed CD25 and produced IFN-gamma upon anti-CD3 plus anti-CD28 stimulation, arguing for a strong regulatory role of this novel T cell population in the mouse female genital tract... - Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient miceAli A Akhiani
Department of Clinical Immunology, Goteborg University, Goteborg, Sweden
J Immunol 173:3348-56. 2004.... - Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infectionAli A Akhiani
Department of Clinical Immunology, University of Goteborg, Gothenburg, Sweden
J Immunol 172:5024-33. 2004.... - Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritisAnnemarie Hasselberg
Mucosal Immunobiology and Vaccine Research Center, Department of Microbiology and Immunology, Sahlgrenska Academy, University of Goteborg, Goteborg, Sweden
Arthritis Rheum 60:1672-82. 2009.... - The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protectionMarina De Filette
DMBR, Ghent University-VIB, FSVM-Building, Technologiepark 927, B-9052 Ghent (Zwijnaarde, Belgium
Vaccine 24:544-51. 2006..When the vaccine was administered intraperitoneally, the adjuvant improved the M2e antibody titer in circulation, but did not significantly reduce the morbidity... - Improved design and intranasal delivery of an M2e-based human influenza A vaccineMarina De Filette
Department for Molecular Biomedical Research, VIB-Ghent University, FSVM Building, Technologiepark 927, B-9052 Ghent, Zwijnaarde, Belgium
Vaccine 24:6597-601. 2006..These results show that M2e is a valid and versatile vaccine candidate to protect against any strain of human influenza A... - Facial nerve lesion response; strain differences but no involvement of IFN-gamma, STAT4 or STAT6Olle Lidman
Department of Medicine, Karolinska Institutet, Neuroimmunology Unit, CMM L08;04, Karolinska Hospital, S171 76 Stockholm
Neuroreport 13:1589-93. 2002.... - Laser-Doppler flowmetry is reliable for early diagnosis of small-bowel acute rejection in the mouseGeorge Dindelegan
Surgical Clinic No 1, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Microsurgery 23:233-8. 2003..Laser-Doppler perfusion in the rejecting intestinal allograft was decreased before onset of histological features of rejection. Mucosal blood flow measured by laser-Doppler could be used as an early indicator of acute rejection in SBT...